INTRODUCTION {#s1}
============

Traumatic brain injury (TBI), is a leading cause of death among adults \[[@R1]\]. The term TBI refers to a diverse group of head injuries in which a patient receives a Glasgow Coma Scale (GCS) score between 3 and 8. Much progress has been made in the prevention and treatment of TBI over the last 20 years yet nearly 2 million people sustain a TBI annually in the United States, contributing to one-third of all injury-related deaths \[[@R2]\]. In general, the damage induced by TBI is divided into two types: primary and secondary brain injuries. Primary injury is initiated by a physical insult to the head, resulting in compression and shearing of adjacent tissues with or without loss of consciousness. Secondary injury is a complex process that occurs in the hours and days following primary injury, which encompass cranial and systemic complications. Cranial complications may include cerebral edema \[[@R3]\], intracranial hypertension \[[@R4]\], infection \[[@R5]\], calcium ion toxicity \[[@R6]\] and vasospasm \[[@R7]\]. Systemic complications are mainly ischemic in nature \[[@R8]\], and include hypoxemia\[[@R8]\]\[[@R9]\], hypotension, hypertension \[[@R8]\], hyperglycemia, and hypoglycemia \[[@R10]\]. Among these secondary complications, hyperglycemia (both peak glucose and persistent hyperglycemia) in TBI patients is one of the most common and correlates with the severity of the injury and clinical outcome \[[@R11], [@R12]\]. Furthermore, the link between hyperglycemia and poor prognosis is also observed in ischemic stroke, subarachnoid hemorrhage, and intracerebral hemorrhage \[[@R13]--[@R15]\]. Importantly, as treatments for hyperglycemia become available, blood glucose control has attracted significant attention as a promising intervention for reducing the complications of TBI.

Previous studies have demonstrated that hyperglycemia plays a causative role in promoting poor clinical outcomes in TBI. In this review, we summarize the potential causes and effects of hyperglycemia in TBI patients and attempt to address the pathological mechanisms that might explain the association of hyperglycemia with poor clinical outcomes. Furthermore, we perform a systematic review of research studying glycemic control in TBI patients and provide some direction for future clinical prevention and treatment.

THE BRAIN AND GLUCOSE (FIGURE [1](#F1){ref-type="fig"}) {#s2}
=======================================================

Glucose is the predominant source of energy for the mammalian brain \[[@R16]\]. Glucose entry into the brain is facilitated by the transporter, GLUT1, which is found in the blood-brain barrier (BBB). GLUT1 mediates glucose uptake from extracellular fluid into astrocytes, microglia and oligodendroglia, whereas transporter GLUT3 facilitates neuronal glucose uptake \[[@R17], [@R18]\]. Compared to other cells in the adult brain, neurons and astrocytes have a stronger demand for glucose. However, the underlying relationships between neuronal and astrocytic glucose utilization have remained controversial for decades because current technologies do not possess adequate resolution to quantify metabolic activity in a single cell *in vivo* \[[@R17], [@R19], [@R20]\].

To date, there are two conflicting theories describing the cellular fate of glucose, and which propose different directions for lactate shuttling between neurons and astrocytes. These are termed the astrocyte-neuron lactate shuttle (ANLS) and the neuron-astrocyte lactate shuttle (NALS). The ANLS theory proposes that glucose is transported into astrocytes through the GLUT1 transporter and then metabolized to lactate \[[@R21], [@R22]\]. Lactate is transported to the outside of astrocytes and taken up by neurons and served as fuel through monocarboxylate transporters (MCTs) \[[@R23]\]. The NALS model predicts that neurons uptake glucose during activation and then transfer lactate to astrocytes \[[@R24]\]. Interestingly, if glucose and lactate are both present, neurons appear to have a preference for lactate \[[@R23]\]. Both neurons and astrocytes have strong demands for energy and are largely intolerant of inadequacy of energy supplies. Therefore, disruption of glucose shuttling and/or metabolism may result in various central nervous systemic pathologies \[[@R25], [@R26]\], and it may be important to rigorously define the relationship between glucose metabolism in brain cells and cerebral diseases.

![Cellular fate of glucose between neurons and astrocytes](oncotarget-07-71052-g001){#F1}

MECHANISMS OF HYPERGLYCEMIA AFTER TRAUMATIC BRAIN INJURY (FIGURE [2](#F2){ref-type="fig"}) {#s3}
==========================================================================================

In a 4-year study of 149 patients with TBI, those with severe TBI had greater admission blood glucose levels compared to those with mild TBI \[[@R27]\]. This initial hyperglycemia was associated with increased mortality (37% in the hyperglycemia group versus 8% in the normoglycemia group), indicating a close relationship between TBI and glucose levels \[[@R28]\]. Thus, exploring the underlying causes leading to hyperglycemia after TBI may provide new treatment options. The following sections address a number of mechanisms by which hyperglycemia is induced following TBI.

Stress response {#s3_1}
---------------

There are several explanations for high glucose levels after TBI, and one of the most studied is stress-induced hyperglycemia. During a 4-year study, a total of 626 patients were enrolled with severe TBI defined by GCS score from 3 to 8. Among 184 patients admitted with hyperglycemia, 152 (82.6%) were diagnosed with stress-induced hyperglycemia (SIH) and 32 patients (17.4%) were diagnosed with diabetic hyperglycemia (DH). Patients with SIH had a 50% increased mortality as compared to nondiabetic hyperglycemia patients, whereas DH patients did not have a significant increase in mortality \[[@R29]\]. During TBI, the hypothalamic-pituitary-adrenal axis and the sympathetic autonomic nervous system are activated, resulting in increased levels of neuro-hormonal factors and insulin resistance.

First, the increased levels of stress hormones may influence glycemic levels. After TBI, the activation of the hypothalamic-pituitary-adrenal axis and the sympathetic autonomic nervous system induce elevated blood levels of catecholamine, cortisol, glucagon and growth hormone, which enhance glycogenolysis and hypermetabolism and lead to excessive glucose production \[[@R29], [@R30]\]. By functioning on islet beta cells\' alpha 2 receptor, catecholamines also increase glucagon production and decrease insulin secretion \[[@R31], [@R32]\]. Second, transient insulin resistance (IR) is another mechanism by which stress hormones may affect glucose metabolism. Several reports have demonstrated that TBI reduces insulin sensitivity and secretion, contributing to IR and glucose homeostasis impairment \[[@R33]\]. The released catecholamines can inhibit glucose transport *via* inhibition of insulin binding, leading to IR with hyperinsulinemia \[[@R34]\].

Inflammatory response {#s3_2}
---------------------

TBI is accompanied by a systemic inflammatory response syndrome (SIRS), in which there may be two mechanisms that lead to hyperglycemia. First, during the inflammatory response, several cytokines are released, including TNF-α, IL-6, and CD11d \[[@R35]\]. Studies demonstrated that TNF-α regulated quantity and function of glucose by decreasing levels of adipocyte-specific genes and increasing levels of preadipocyte-specific genes, contributing to insulin resistance and hyperglycemia \[[@R36]\]. Second, inflammatory responses increase the level of corticotrophin-releasing hormone (CRH) and stimulate the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, which induce elevated levels of blood glucose. Nitric oxide (NO), which is activated in the inflammatory response, participates in signal transduction pathways that lead to the release of corticosterone from the adrenal gland, and finally results in hyperglycemia. \[[@R37]\]. While not still understood, the interaction between inflammatory response and hyperglycemia is clearly important and warrants further investigation.

Diabetes mellitus (DM) {#s3_3}
----------------------

Diabetes mellitus (DM) is another source of hyperglycemia in this setting. Severe TBI with DM has a higher mortality (14%) compared to severe TBI without DM (8.2%), and TBI with insulin-dependent DM (IDDM) has a higher mortality rate (17.1%) than patients without insulin-dependent DM (NIDDM). These results indicate that insulin deficiency may contribute to the increased mortality after TBI, and DM has the potential to be an independent predictor of poor outcome and mortality after TBI \[[@R38], [@R39]\]. Latent diabetes mellitus may be particularly problematic, especially in elderly patients. The symptoms of DM can be exacerbated after severe TBI, and undiagnosed DM may contribute to insulin resistance without characteristic clinical symptoms \[[@R40]\].

Pituitary and hypothalamic dysfunction {#s3_4}
--------------------------------------

Pituitary and/or hypothalamic dysfunction following TBI is a significant occurrence that is rarely considered by clinicians. Recently, this topic has attracted some attention owing to high prevalence of pituitary or hypothalamic dysfunction after moderate-severe TBI and its association with increased morbidity and poor recovery \[[@R41]\]. In addition to its role in regulating the stress response, the hypothalamus-pituitary axis is vital for balancing glucose homeostasis, acting to decrease hepatic gluconeogenesis and increase insulin sensitivity \[[@R42]\]. Pituitary dysfunction directly leads to impaired glucose metabolism and may act as a potential cause of hyperglycemia \[[@R43]\]. In addition, injury of the pituitary leads to disorders of neuroendocrine function \[[@R44], [@R45]\], and, amongst these, deficiency of gonadotrophic hormones and growth hormones are commonly induced by TBI and may result in an imbalance of glucose metabolism \[[@R46]\]. Thus, pituitary/hypothalamic dysfunction may contribute significantly to hyperglycemia in TBI patients.

Iatrogenic factors {#s3_5}
------------------

There are several other explanations of hyperglycemia induced by TBI. Surgery,anaesthesia, treatment strategies (including too high a dosage of hyperosmotic glucose or a high calorie substance), and psychological factors, may also lead to hyperglycemia in TBI patients, especially in severe TBI \[[@R47], [@R48]\].

In conclusion, an elevated stress and inflammatory response seem to be the major causes of hyperglycemia after TBI. Preexisting hyperglycemia does not seem to have a predominant role in TBI patients, and a relationship between pituitary and/or hypothalamic dysfunction, iatrogenic factors, and hyperglycemia is plausible.

HYPERGLYCEMIA AND CLINICAL OUTCOMES AFTER TRAUMATIC BRAIN INJURY {#s4}
================================================================

During one study, a total of 267 patients with moderate or severe TBI (GCS scores 3-12) were admitted. Patients with severe TBI had significantly higher glucose levels than those with moderate injury. Furthermore, patients who subsequently had an unfavorable outcome had higher glucose levels (\>200 mg/dL or\>11mmol/L) than did those with a better prognosis \[[@R11]\]. In addition, the relationship between high blood glucose levels and poor outcome after TBI appears to be more pronounced with persistent hyperglycemia (PH) than solely hyperglycemia on admission \[[@R49]\]. One study showed that PH was an independent predictor of clinical outcome in severe TBI, and PH was associated with higher mortality rates in patients with severe TBI \[[@R50]\]. These studies beg the question: How exactly does hyperglycemia affect outcomes after traumatic brain injury? (Figure [2](#F2){ref-type="fig"}) Here we show that hyperglycemia may increase the damage of nerve function and brain structure in a number of ways.

![Figure illustrating hypothetical mechanisms: hyperglycemia in patients with traumatic brain injury (upper panel); and explaining a detrimental effect of hyperglycemia on clinical outcome (lower panel)\
BBB, blood-brain barrier.](oncotarget-07-71052-g002){#F2}

Lactic acidosis {#s4_1}
---------------

In the early stages after severe TBI, local blood flow decreases \[[@R51]\]. During ischemic and hypoxic conditions, hyperglycemia inhibits the tricarboxylic acid cycle (TCA) and promotes anaerobic glycolysis, contributing to the accumulation of lactic acid and disturbance of pH homeostasis. In support of a detrimental function of lactic acid is the discovery that in patients with severe TBI, hyperglycemia is associated with both intracellular acidosis and disruption of BBB, eventually leading to ischemia, edema and necrosis \[[@R52], [@R53]\]. Additionally, injured nerve cells cannot metabolize the excess glucose using the mitochondrial aerobic metabolic pathway, causing general decreased glucose utilization \[[@R54]\]. Finally, severe TBI or a reduced blood supply leads to increased metabolism of local brain tissues further stimulating glycolysis \[[@R55]\]. The above pathways promote accumulation of lactic acid and eventually contribute to dysfunctional energy metabolism in nerve cells.

Electrolyte disturbances {#s4_2}
------------------------

Within minutes after TBI, dysfunctional energy metabolism and lactic acidosis lead to increased intracellular Ca^2+^, causing cellular toxicity and the accumulation of free fatty acid (FFA) and glutamate \[[@R56], [@R57]\]. Excessive glutamate promotes increased Na^+^ and Ca^2+^ to enter into cells, and the resulting intracellular Ca^2+^ overload stimulates cell damage *via* caspase activation \[[@R58]\]. As astrocytes represent the main defense by absorbing glutamate, an initial glutamate excitotoxicity occurs in neurons \[[@R59]\]. However, during the secondary injury stage, if extracellular glutamate levels are constantly increased, the expression of glutamate transporters (glutamate transporter-1, GLT-1) and the glutamate-aspartate transporter (GLAST) decreases, and the intracellular Na^+^ can reverse transport. This event favors the release of glutamate from astrocytes rather than neurons, and the astrocytes actually enhance glutamate excitotoxicity \[[@R60], [@R61]\]. Additionally, a relatively large amount of lactic acid leads to reduced ATP and impairs the Na^+^-K^+^-ATPase causing excessive extracellular Na^+^ levels and cell edema that ultimately results in intracranial hypertension and cerebral hernia \[[@R62]\].

Inflammation {#s4_3}
------------

Hyperglycemia after severe TBI is associated with an increase in pro-inflammatory cytokines and pro-inflammatory transcription factors, such as transforming growth factor (TGF-β), interleukin 1β (IL1-β) and tumor necrosis factor-α (TNFα) \[[@R63], [@R64]\]. These cytokines increase significantly in the peripheral blood, cerebrospinal fluid, and brain tissue after TBI, which closely correlates with the severity and bad outcome of TBI patients \[[@R65]\]. An *in vitro* experiment demonstrated that hyperglycemia induced by walnut oil increased the release of pro-inflammatory cytokines, which led to reduced antioxidant capacity and oxidative DNA damage of human monocytic cells (U937) \[[@R66]\]. Furthermore, microglia activation and endothelial cell damage induced by inflammation after TBI could lead to brain injuries, such as edema \[[@R67]\]. Therefore, cytokines play an important role in the neuropathology of TBI, and inhibition of these cytokines indeed had a correlation with neuroprotective effects after TBI, especially the improvement of brain edema and neurological outcomes \[[@R68]\].

Other effects {#s4_4}
-------------

Hyperglycemia can affect clinical outcomes in other ways. For instance, hyperglycemia can directly cause increased blood viscosity and diffuse small vessel disorders, resulting in ischemia and hypoxia in the brain tissues \[[@R69]\]. Additionally, hyperglycemia exacerbates edema of endothelial cells, impairs glial cells, and can induce the rupture of the BBB \[[@R70], [@R71]\]. Hyperglycemia also has the potential to accelerate cerebral vasospasm \[[@R72]\]. Thus, the causal relationship between hyperglycemia and poor clinical outcome in TBI patients may be multifactorial. In the sequence of insults that occur after TBI, hyperglycemia may play a detrimental role by elevating secondary complications such as dysregulated energy metabolism, infection, intracranial edema, and intracranial hypertension.

MANAGEMENT OF HYPERGLYCEMIA IN PATIENTS WITH TRAUMATIC BRAIN INJURY {#s5}
===================================================================

As discussed, hyperglycemia may manifest poor outcomes after TBI through several responses. Besides lowering blood glucose with insulin, there are additional strategies clinicians can use to normalize glucose homeostasis that are potentially relevant in this setting. Current thinking suggests that comprehensive measures should be taken to address hyperglycemia after TBI.

Nutritional support {#s5_1}
-------------------

Patients with severe TBI are usually in catabolic and hyperglycemic states, and may have gastrointestinal dysfunction \[[@R73]\]. Previous studies have shown that malnutrition is associated with a higher mortality rate in severe TBI patients, and early effective nutritional support may improve insulin resistance and patient prognosis \[[@R74]\]. Furthermore, studies have demonstrated that enteral feeding has greater advantages than parenteral nutrition (PN), which may be attributed to the following: 1) enteral feeding is relatively safe, cheap, cost-effective, and more physiologic; 2) enteral feeding stimulates all gastro-intestinal tract functions;; and 3) enteral feeding preserves the immunological gut barrier function and reduces septic complications \[[@R75]\]. It is also worth noting that a large amount of glucose (intravenous and enteral feeding) can have harmful effects on outcome in TBI patients, thus clinicians should strictly limit the dosage of glucose, which includes both intravenous glucose and enteral feeding with low carbohydrates \[[@R76]--[@R78]\].

Glucose control {#s5_2}
---------------

Insulin increases glucose utilization and reduces the damage of hyperglycemia to brain cells \[[@R79]\]. Owing to insulin resistance after TBI, most studies use exogenous insulin and dynamically monitor blood glucose to fight against hyperglycemia after TBI \[[@R79]\]. In 2001, intensive insulin therapy (IIT) was implemented in intensive care units (ICUs) worldwide after a landmark clinical trial, which demonstrated clinical benefits of IIT in a surgical ICU \[[@R80]\]. However, several later trials could not confirm the findings of this study, one study demonstrated that maintaining low blood glucose with IIT (a blood glucose target of 81-108 mg/dL (4.5-6 mmol/L)) was in fact associated with an increased risk of mortality and even hypoglycemia (glucose\<40 mg/dL (2.2 mmol/L)), which may be due to the effects of IIT on cerebral glucose homeostasis after severe TBI \[[@R81], [@R82]\]. Another study also showed that IIT results in a net decrease in microdialysis glucose but an increase in microdialysis glutamate and lactate/pyruvate, with an adverse effect on the long-term recovery of neurological function \[[@R83]\]. Therefore, in patients with severe TBI, decreased glucose levels with insulin can induce and aggravate secondary brain injury.

Because of these conflicting findings, blood glucose control in TBI has recently been the topic of much research \[[@R84]\]. One retrospective study enrolled a total of 228 patients suffering from severe TBI that were treated with insulin. In the first week (acute stage), a blood glucose target of 90-144 mg/dL (5-8 mmol/L) was associated with reduced mortality rate and decreased intracranial pressure (ICP) compared to a blood glucose target of 63-117 mg/dL (3.5-6.5 mmol/L). However, in the second week, the groups appeared to have the reverse outcomes: compared with the 5-8 mmol/L target group, the 3.5-6.5 mmol/L group demonstrated a decreased incidence of ICP and reduced infectious complications. Therefore, a slightly higher blood glucose (5-8 mmol/L) seems to provide benefits during the first week while lower blood glucose (3.5-6.5 mmol/L) may be more favorable during the later stages of recovery \[[@R79]\]. Another study demonstrated that blood glucose \< 6-11 mmol/L could reduce mortality in patients with mild TBI, while in patients with severe TBI, the ideal target of blood glucose was 7.77-10.0 mmol/L. Consequently, the debate on blood glucose levels in TBI is still controversial and needs to be further explored \[[@R76]\].

Other treatments {#s5_3}
----------------

There are also other strategies that can augment glucose control in the clinical setting. First, during a randomized controlled study in patients with severe TBI, moderate hypothermia was induced within 24 hours of injury, and the hypothermic group (198 cases, rectal temperature 32.0°C to 35.0°C) was found to have a lower incidence of ICP and decreased levels of glucose compared to the control group (198 cases, rectal temperature 36.5°C to 37.0°C) \[[@R85]\]. Multivariate regression analysis revealed that blood glucose greater than 10 mmol/L was an independent predictor for a poor outcome after severe TBI. In this clinical study, blood glucose in the hypothermia group was 100% less than 10 mmol/L, compared to 75.6% in the normothermia group after 3 days of treatment, which may be associated with the better recovery observed in patients \[[@R86]\]. Second, the application of naloxone, an opioid receptor antagonist, may effectively exert anti-inflammatory effects and improve the metabolism of brain cells in the early stages of severe TBI; on the other hand, naloxone also relieves calcium overload and prevents the toxicity of excitatory amino acids \[[@R87], [@R88]\]. Third, mannitol or hypertonic saline administration are effective ways of decreasing hyperpermeability and raised ICP induced by hyperglycemia after severe TBI \[[@R89], [@R90]\].

CONCLUSIONS {#s6}
===========

Hyperglycemia (both peak glucose and persistent hyperglycemia) is one of the most common secondary complications of severe TBI and is associated with poor clinical outcomes after this type of injury. In this review, we have summarized the mechanisms leading to hyperglycemia after TBI, including stress response, inflammatory response, diabetes mellitus, pituitary and/or hypothalamic dysfunction, surgery, and anaesthesia. TBI patients with hyperglycemia possess an increased risk of poor outcome and an increased mortality rate, which is more pronounced with persistent hyperglycemia (PH) than hyperglycemia on admission \[[@R49]\]. Some of the direct effects of hyperglycemia may be attributed to lactic acidosis, electrolyte disturbances, inflammation, vessel disorders, rupture of the BBB, and hyperpermeability. At present, the treatments of secondary brain injury with hyperglycemia may include nutritional support, glucose control, moderated hypothermia, naloxone, and mannitol. Although the relationship between hyperglycemia and severe TBI has made great progress in recent years, there are still many treatment limitations and gaps in our current knowledge.

One such gap is the best definition of an optimal target range of blood glucose. To date, the optimal glycemic target range is uncertain and may not be uniform among TBI patients, varying between individuals at different time points during the clinical course. Cerebral microdialysis, which is defined as a neurochemical research tool in neurointensive care, can be widely used to monitor the metabolic state of the injuried brain and discover metabolic crises established as low/high glucose level or high lactate/pyruvate ratio, and may facilitate the identification of a safe and effective glycemic target range \[[@R91], [@R92]\]. In addition, although the technology for studying brain cell metabolism has advanced significantly, research should focus on examining the relationship between brain cell metabolism and hyperglycemia after severe TBI.

There is not widespread agreement on the best way to approach glycemic control in patients with TBI. Several studies have suggested that a large scale randomized controlled trial (RCT) may provide convincing proof of glucose control in future treatments. As previously mentioned, the therapy of IIT for hyperglycemia post TBI remains controversial to date, and the treatment comes at the cost of an increased risk of hypoglycemia (glucose \< 2.2 mmol/L). Therefore, methods to improve IIT without inducing secondary complications should be investigated, and attention should also focus on the prevention of hypoglycemia in severe TBI patients. Multidisciplinary teams should play a role in providing individual treatments for hyperglycemia in TBI patients, including diabetic and TBI experts to facilitate the implementation of glucose control protocols aimed at lowering blood glucose without secondary complications. During the clinical course, close monitoring of blood glucose and frequent adjustment of insulin is strongly recommended \[[@R93]\].

In conclusion, hyperglycemia is one of the most common and serious secondary complications of severe TBI. Future studies are needed to explore an optimal and safe glycemic target range, to facilitate critical care of blood glucose control and to further research the relationship between brain cell metabolism and hyperglycemia after severe TBI.
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